StealthAIBio

StealthAIBioStealthAIBioStealthAIBioStealthAIBio

StealthAIBio

StealthAIBioStealthAIBioStealthAIBio

AI-Powered Asset Selection and Commercialization

AI-Powered Asset Selection and CommercializationAI-Powered Asset Selection and CommercializationAI-Powered Asset Selection and Commercialization

AI-Driven Asset Identification & Commercialization

At StealthAIBio, we use advanced AI to identify high-potential biopharmaceutical assets and design lean, evidence-based commercialization strategies. Our platform integrates real-world data, clinical insights, and market dynamics to pinpoint asymmetric opportunities and accelerate go-to-market execution.

Team

Dillon Shokar

Dillon Shokar

Dillon Shokar

  • Background: Biopharma founder and operator with 10+ years of industry experience
  • Expertise: Evidence generation, market access, and commercialization 
  • Education: Biostatistics at King’s College London

Connor S.

Dillon Shokar

Dillon Shokar

  • Background: Practicing physician and biopharma strategy consultant
  • Expertise: Clinical strategy and therapeutic asset evaluation
  • Education: Ecology at Princeton University, Medicine at Columbia University

Peter H.

Dillon Shokar

Peter H.

  • Background: VP of Data Engineering at Goldman Sachs
  • Expertise: Complex algorithmic systems and large-scale data infrastructure
  • Education: Physics at Yale University

Copyright © 2025 StealthAIBio - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept